How Oneview Healthcare (ASX:ONE) Delivered a Record Quarter for New Customer Acquisition in Q3 2026

Sonal Goyal

03 November 2026 11:57 PM AEDT

How Oneview Healthcare (ASX:ONE) Delivered a Record Quarter for New Customer Acquisition in Q3 2026

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Record quarter with six new customer logos added in Q3 2026, including four new Bedside Hub TV deployments, placing the company ahead of its previously stated target of three to four new Bedside Hub customers in the second half
Pro-forma cash balance of approximately €8.6 million (A$13.7 million) at 26 October 2026, including pending Tranche 2 of a A$19 million institutional Placement subject to Shareholder approval at the 25 November AGM
Four new Bedside Hub customers together represent a combined footprint of almost 5,000 beds, providing expansion opportunity beyond the initial deployments
AI-powered Ovie Digital Care Assistant advancing toward first customer deployment with a major US healthcare system, with pilot formally commencing in November 2026

Oneview Healthcare PLC (ASX:ONE) reported its strongest quarter for new customer Acquisition in the company's history during the three months ended 30 September 2026, adding six new customer logos across its product suite. The result places the company materially ahead of the guidance it provided in its Q2 update, where it had targeted three to four new Bedside Hub customers in the second half of 2026 — four new Bedside Hub customers have already been added since that target was communicated.

The four new Bedside Hub TV customers represent healthcare organisations operating across academic, regional and specialist settings in the United States, providing geographic and institutional diversity to what is a growing installed base for the company's Epic MyChart-integrated hardware offering. Those four organisations collectively operate a combined footprint of almost 5,000 beds, establishing a significant expansion opportunity beyond the initial contracted deployments.

Bedside Hub Customer Details

The four new Bedside Hub TV customers announced during the quarter include Cape Fear Valley Health in North Carolina, a public hospital authority with more than 1,000 licensed beds and the region's only Level II trauma centre. A second customer is Boca Raton Regional Hospital in Florida, a 400-bed community hospital and member of Baptist Health South Florida. Two further customers are New Hanover Regional Medical Center and Treasure Coast.

The company noted that its healthcare-grade hardware and cloud-based device management solution for Epic MyChart Bedside TV is demonstrating the potential for a faster path to customer acquisition, with two of these new opportunities having progressed from first contact to signing in fewer than three months. This shortened sales cycle is significant for a company that has historically operated in an enterprise software environment where procurement processes can span 12 months or more.

Care Experience Platform Adds Two More Customers

Beyond the Bedside Hub wins, Oneview secured two additional customers for its Care Experience Platform. Martin Luther King, Jr. Community Hospital — a 131-bed private not-for-profit hospital serving South Los Angeles — and Northeastern Vermont Regional Hospital, a 25-bed critical access hospital serving Vermont's Northeast Kingdom, both joined the platform during the quarter. The Care Experience Platform additions broaden the company's reach into smaller and community-based hospital settings alongside the larger systems targeted by the Bedside Hub offering.

AI Product Advancement Toward First Deployment

Product development progress during the quarter was notable for the advancement of the AI-powered Ovie Digital Care Assistant from pilot planning into active pre-deployment preparation. A major US healthcare system has initiated its AI Governance process, with preparation underway for deployment to a customer environment in Q4 2026. The pilot is scheduled to formally commence in November 2026. The Beta pilots are designed to validate the technology, user experience and operational workflows before the product moves toward general availability.

Oneview also completed the first customer deployment of its redesigned patient user interface, with initial feedback described as very positive regarding improved user experience, visual design and responsiveness. A second deployment with a major US customer is underway, with a phased migration of existing customers during 2027.

Cash Flow and Financial Position

Oneview's cash balance at 30 September 2026 was €2.4 million (A$3.9 million), reduced from €7.2 million (A$11.9 million) at 30 June 2026. The company reported that the end-of-September balance was negatively impacted by a delayed receipt of an annual customer renewal fee of US$2.23 million that was due in the quarter but not received until 19 October 2026. By 26 October 2026, the cash balance had recovered to €4.2 million (A$6.7 million).

The company completed the first tranche of a A$19 million institutional placement in March 2026, raising A$12 million. Tranche 2, which will raise a further A$7 million, remains subject to shareholder approval at the Annual General Meeting to be held on 25 November 2026. On a pro-forma basis with Tranche 2 included, the cash balance at 26 October would have been approximately €8.6 million (A$13.7 million).

Risks

Oneview reported a net operating cash outflow for the quarter, and the company continues to rely on its cash reserves and the forthcoming Tranche 2 placement proceeds while progressing toward a larger contracted Revenue base. The delayed receipt of a major customer renewal payment illustrates the Cash Flow timing variability inherent in the company's annual subscription model. The Bedside Hub product is relatively new, and while the initial customer wins are encouraging, the pace of expansion within each customer's full bed base will determine the longer-term revenue trajectory. Shareholder approval for the Tranche 2 placement at the November AGM is required to access the remaining A$7 million.

What to Watch Next

The shareholder vote on Tranche 2 of the placement at the 25 November AGM is the most immediate corporate event. The November commencement of the Ovie AI pilot at a major US healthcare system will be watched as a product validation milestone. Progress toward the company's stated target of finishing the year with between 8 and 10 new customer logos — having already added 6 — will determine whether this record quarter translates into full-year momentum. Expansion of the Bedside Hub footprint within newly signed customer organisations will be a key revenue growth driver into 2027.

Sector Context

Healthcare IT companies serving US hospital networks operate in a large and growing market driven by regulatory requirements, patient experience expectations and the increasing adoption of AI in clinical environments. Oneview's position as a certified Epic MyChart integration partner for Bedside TV places it within a high-value segment of the hospital technology stack, as Epic dominates the US electronic health record market. The company's ability to demonstrate a shortened sales cycle for the Bedside Hub product is a meaningful commercial development, as sales velocity is a critical metric for SaaS-model companies seeking to achieve Operating Leverage on their customer acquisition investment.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.